The concern of generic competition has consistently loomed above copyright’s famous drug, PDE5 Inhibitor, raising questions about the prospects of connected drug portfolios. While first times saw impressive gains, the exclusivity end has allowed the path for cheaper copies, likely reducing revenue and posing a genuine risk for stakeholders seekin